Prevalence of the Victimization and the Perpetration of Intimate Partner Violence Among the Patients From Puy-de-Dôme and Paris Consulting or Being Hospitalized for Addiction Problems and Their Expectations From General Practitioners (VIA-MG) (VIA-MG)

July 30, 2026 updated by: University Hospital, Clermont-Ferrand

Prevalence of the Victimization and the Perpetration of Intimate Partner Violence Among the Patients From Puy-de-Dôme and Paris Consulting or Being Hospitalized for Addiction Problems and Their Expectations From General Practitioners

Intimate partner violence and addictions are two frequent problematics with many consequences on health. A link between intimate partner violence and addictions has been found in many studies. Being a drug user increases the risk to be a perpetrator and also a victim of intimate partner violence.

So, it is legitimate to question ourselves about the prevalence of the victims and perpetrators of intimate partner violence among the patients consulting or being hospitalized for an addiction problem. We believe that this prevalence will be high among these patients.

On the other hand, the general practitioners are in first line receiving victims and perpetrators of violence and patients with addiction problems. So it is important to know the profiles of these patients and their expectations from their general practitioners.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The different places where the study will take place are:

  • 7 outpatient addiction centers: Addictology consultations in CHU Clermont-Ferrand, CH Sainte-Marie, CH Thiers, CH Ambert, ANPAA (Association Nationale de Prévention en Alcoologie et en Addictologie) of Clermont-Ferrand, Thiers and Ambert.
  • 3 hospital addiction centers: Addictology hospital services of CHU of Clermont-Ferrand, CH Thiers and Clémentel.

This study will be based on the filling of self-answered questionnaires by the patients consulting or being hospitalized in the different recruited centers. The questionnaire will be proposed to the patient after the consultation with the practitioner. An information about the study and the anonymity will be given to the patient. The filled questionnaire will be put by the patient in a closed envelope and then in a collection box located in the waiting room.

The different boxes of the different centers will be checked regularly and then the questionnaires will be analysed. The analysis of these questionnaires will allow to describe the population consulting or being hospitalized for addiction problems in the Puy-de-Dôme: age, gender, type of the addiction, the presence of intimate partner violence, associated factors of the violence, recourse characteristics to general practitioners and expectations of GP. We will evaluate the prevalence of victimization and perpetration of intimate partner violence among patients consulting or being hospitalized for addiction problems in the Puy-de-Dôme.

We estimate the duration of the study at around 6 months.

Study Type

Observational

Enrollment (Actual)

122

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Clermont-Ferrand, France, 63000
        • CHU de Clermont-Ferrand

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients consulting or being hospitalized for addiction problems

Description

Inclusion Criteria:

  • Patient over 18, being or having been in a relationship, consulting or being hospitalized for an addiction problem
  • Patient speaking and writing French
  • Patient capable of giving his informed consent to take part to the study
  • Affiliation to the social security
  • Patient who doesn't have a tobacco addiction only

Exclusion Criteria:

  • refuse to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patient consulting or hospitalized in addiction structure
Other: questionnaire
questionnaire for conjugal violence prevalence

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of the victimization
Time Frame: day 0
Prevalence of the victimization and the perpetration of intimate partner violence in patients consulting or being hospitalized for addiction problems who had filled the questionnaire. This prevalence will be measured by the filling of the questions of the self-answered questionnaire by the patients.
day 0

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of each addiction
Time Frame: Day 0
prevalence will be measured by the filling of the questions of the self-answered questionnaire by the patients.
Day 0
Socio-demographic characteristics
Time Frame: Day 0
age in years
Day 0
Socio-demographic characteristics
Time Frame: Day 0
male or female
Day 0
Recourse at general practitioner characteristics
Time Frame: Day 0
reason and frequency of consultation with their general practitioner
Day 0
Expectations by the patients of the general practitioners about addictions and intimate partner violence
Time Frame: Day 0
qualitative answer
Day 0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Clermont-Ferrand

Collaborators

General medicine department of Clermont-Ferrand's university

Investigators

  • Principal Investigator: Mathilde VICARD-OLAGNE, University Hospital, Clermont-Ferrand

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2022

Primary Completion (Actual)

July 20, 2022

Study Completion (Actual)

July 20, 2022

Study Registration Dates

First Submitted

December 6, 2021

First Submitted That Met QC Criteria

December 6, 2021

First Posted (Actual)

December 20, 2021

Study Record Updates

Last Update Posted (Actual)

July 31, 2026

Last Update Submitted That Met QC Criteria

July 30, 2026

Last Verified

July 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RNI 2021 VICARD-OLAGNE
  • 2021-A01356-35 (Other Identifier: ANSM)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe